Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GALT 
Galectin Therapeutics Inc (GALT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: GALT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 34.38% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 95.40M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 272983 | Beta 0.69 | 52 Weeks Range 0.73 - 4.27 | Updated Date 03/30/2025 |
52 Weeks Range 0.73 - 4.27 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Earnings Date
Report Date 2025-03-27 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -96.72% | Return on Equity (TTM) -3727.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 175146974 | Price to Sales(TTM) - |
Enterprise Value 175146974 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.04 | Shares Outstanding 62761800 | Shares Floating 43965914 |
Shares Outstanding 62761800 | Shares Floating 43965914 | ||
Percent Insiders 31.13 | Percent Institutions 16.26 |
Analyst Ratings
Rating 3 | Target Price 11 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Galectin Therapeutics Inc
Company Overview
History and Background
Galectin Therapeutics Inc. was founded in 2000. It is a biopharmaceutical company focused on developing therapies for fibrotic diseases and cancer. It has primarily focused on developing Galectin-3 inhibitors.
Core Business Areas
- Drug Development: Research, development, and clinical trials of Galectin-3 inhibitors, primarily focused on non-alcoholic steatohepatitis (NASH) with cirrhosis and other fibrotic diseases.
Leadership and Structure
The leadership team consists of experienced professionals in the pharmaceutical industry, including the CEO, Chief Medical Officer, and other key executives. The organizational structure is typical of a biopharmaceutical company, with departments focused on research, clinical development, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Belapectin: Belapectin is Galectin Therapeutics' lead drug candidate, targeting NASH cirrhosis. It is currently undergoing clinical trials. No current market share as the drug is not approved yet. Competitors in NASH drug development include Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with a focus on developing innovative therapies for unmet medical needs. The NASH market is particularly attractive, with a growing prevalence of the disease and a lack of approved treatments.
Positioning
Galectin Therapeutics is positioned as a company focused on Galectin-3 inhibition, a novel approach to treating fibrotic diseases. Its competitive advantage lies in its proprietary technology and its focus on a specific target.
Total Addressable Market (TAM)
The NASH market is estimated to be in the tens of billions of dollars. Galectin Therapeutics is positioned to capture a portion of this market if Belapectin is approved.
Upturn SWOT Analysis
Strengths
- Proprietary Galectin-3 inhibitor technology
- Experienced management team
- Focus on a large and underserved market (NASH)
- Promising preclinical and clinical data for Belapectin
Weaknesses
- Single product pipeline (Belapectin)
- High cash burn rate
- Dependence on clinical trial success
- Limited revenue generation
Opportunities
- Positive clinical trial results for Belapectin
- Partnerships with larger pharmaceutical companies
- Expansion of the pipeline to include other Galectin-3 inhibitors
- Potential for orphan drug designation
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing NASH therapies
- Market access challenges
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- GILD
- ICPT
Competitive Landscape
Galectin Therapeutics competes with other pharmaceutical companies developing NASH therapies. Its advantages include its novel Galectin-3 inhibition approach. Its disadvantages include its single-product pipeline and limited financial resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been dependent on clinical trial advancements and funding. The company has not had consistent revenue growth.
Future Projections: Future growth is heavily reliant on the successful development and commercialization of Belapectin. Analyst estimates vary widely depending on trial outcomes.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Belapectin in NASH cirrhosis and efforts to secure funding for further development.
Summary
Galectin Therapeutics is a high-risk, high-reward biopharmaceutical company focused on developing Belapectin for NASH cirrhosis. Its success hinges on positive clinical trial results and regulatory approval. The company faces significant competition and financial challenges, but its novel approach could provide a substantial market opportunity if successful. Investors should closely monitor clinical trial data and financial resources.
Similar Companies
- MDGL
- VKTX
- AKCA
Sources and Disclaimers
Data Sources:
- Galectin Therapeutics Inc. SEC Filings
- Company Website
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in biopharmaceutical companies carries significant risks, including clinical trial failures, regulatory hurdles, and market volatility.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galectin Therapeutics Inc
Exchange NASDAQ | Headquaters Norcross, GA, United States | ||
IPO Launch date 2002-09-09 | President, CEO & Director Mr. Joel Lewis CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://galectintherapeutics.com |
Full time employees 14 | Website https://galectintherapeutics.com | ||
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.